The latest biotech news

News and Trends 14 Feb 2017

Dual HIV Therapy: GSK and Gilead Battle over Whose Drug is the Best

GSK announced Phase III results for dolutegravir, which could reduce triple HIV therapy down to two drugs, but Gilead is trying to prove that its candidate bictegravir is better. GSK and Gilead have announced they will present detailed data backing their candidates for a dual HIV therapy. The battlefield will be the Annual Conference on Retroviruses […]

February 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Feb 2017

Biotech from the Bermuda Islands Brings Good News for Dementia Patients

Axovant Sciences has announced positive preliminary results from a Phase II trial directed at reducing hallucinations in patients with dementia. Axovant Sciences is a biotech located in Bermuda, a British tropical island in the Atlantic ocean. From there, the company develops drugs against dementia. The company was founded by young biotech entrepreneur Vivek Ramaswamy, which has […]

February 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Feb 2017

Germany gains Strength in Allergy Immunotherapeutics

Bencard Allergie is developing ultra-short course allergy immunotherapies, backed by a strong growth in its German market. Bencard Allergie is the German subsidiary of Allergy Therapeutics in the UK, which develops allergy vaccines. The German company was the first to market allergoids for allergen-specific immunotherapies. These are proteins modified to be recognized by immune cells while inducing […]

February 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Feb 2017

A Dutch University Hospital has Halted Amyloid Beta Drug Studies

Despite the popularity of amyloid beta-targeting drugs, none have managed to pass late stage clinical trials, prompting UMC Radboud to halt its own studies. In the latest blow to the amyloid beta hypothesis, Radboud University Medical Centre in Nijmegen, the Netherlands, announced that it will no longer continue studies into drugs targeting misfolded amyloid beta. These […]

February 10, 2017 - 3 minutesmins - By Diana Kwon

antivenom shortage biotechnology antibody

News and Trends 10 Feb 2017

Can Biotech make Antivenoms Better and Cheaper with Antibodies?

Recombinant antibodies have yet to be applied to the treatment of snakebites, a neglected tropical ‘disease.’ Researchers from Denmark investigated the technology and cost of this novel approach in biotech. Bites from venomous snakes are a major public health problem in tropical areas, where 2 to 3 million people are affected every year and an estimated 100,000 […]

February 10, 2017 - 3 minutesmins - By Denise Neves Gameiro

lysogene ipo euronext paris e1486638993948

News and Trends 9 Feb 2017

Gene Therapy Biotech Founded to Save the CEO’s Daughter Goes Public in France

Lysogene has raised €22.6M from its IPO on Euronext Paris that will contribute to the completion of clinical trials to treat the rare genetic diseases. Karen Aiach, CEO of Lysogene, started the company back in 2009 to develop a life-saving treatment for her daughter Ornella with Sanfilippo A. This rare genetic disease severely affects the nervous system of […]

February 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 Feb 2017

Alma Bio Therapeutics is Aiming to Revolutionize the Treatment of IBD

A new immune modulator to treat Inﬂammatory Bowel Diseases (IBD) is the lead asset in development at Alma Bio Therapeutics. We had the opportunity to meet up with the company’s co-founder and CEO, Binah Baum, to hear more about their fresh approach to treating IBD and other autoimmune diseases. Binah Baum, another female leader in […]

February 9, 2017 - 6 minutesmins - By External Contributor

Atriva Therapeutics seed funding Influenza

News and Trends 8 Feb 2017

German Biotech gets Seed Funding to Repurpose Cancer Drugs for the Flu

Atriva Therapeutics has received seed funding to advance the development of a better therapy for influenza in patients at high risk. Atriva Therapeutics was founded in Tübingen, Germany in 2015 with a quite particular aim: repurposing cancer drugs to treat influenza. Two private investors, the Dutch Stichting Participatie Atriva and the German High-Tech Gründerfonds (HTGF) have contributed with […]

February 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

gw pharmaceuticals brain tumor cannabinoid

News and Trends 7 Feb 2017

Cannabinoid Drug Prolongs the Life of Brain Tumor Patients in Phase II Trials

GW Pharmaceuticals announced Phase II results for a cannabinoid drug combination with the potential to increase life expectancy in patients with an aggressive form of brain cancer. GW Pharmaceuticals, one of the coolest biotechs in Cambridge, is developing cannabinoid drugs. Its lead candidate, Epidiolex, could reach the market soon and help treat drug-resistant forms of […]

February 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Isogenica Maverick Therapeutics llama antibodies cancer 1

News and Trends 7 Feb 2017

British Synbio’s Llama Antibodies recruited for Cancer T-Cell Therapy

Isogenica has licensed its synthetic llama antibody library to Maverick Therapeutics, which develops cancer T-cell therapies designed to reduce side effects. Isogenica is a synthetic biology company near Cambridge that develops libraries of therapeutic antibodies. The biotech has granted US-based Maverick Therapeutics licenses to its llamdA VHH antibody library for the discovery, development and commercialization of […]

February 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Feb 2017

Swiss Parkinson’s Biotech raises Massive €29M in Series B from Top European VCs

Top European VCs have invested €29M in Prexton Therapeutics to support two Phase II trials of its lead candidate foliglurax in Parkinson’s. An international team of top European biotech investors has participated in Prexton Therapeutics’ latest financing round. The €29M Series B round was co-led by the Dutch Forbion and the Irish Seroba Life Sciences, […]

February 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Innate Pharma lirilumab leukemia failure

News and Trends 6 Feb 2017

French Biotech’s Checkpoint Inhibitor Fails Phase II Leukemia Trial

Innate Pharma’s checkpoint inhibitor candidate lirilumab missed its primary endpoint in a Phase II trial, which gave a hard blow to the company’s stock. When the stock market opened this morning, Innate Pharma‘s stock went down by almost 25%. The company had just announced the results of a Phase II trial that failed to prove its […]

February 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Dual HIV Therapy: GSK and Gilead Battle over Whose Drug is the Best

Biotech from the Bermuda Islands Brings Good News for Dementia Patients

Germany gains Strength in Allergy Immunotherapeutics

A Dutch University Hospital has Halted Amyloid Beta Drug Studies

Can Biotech make Antivenoms Better and Cheaper with Antibodies?

Gene Therapy Biotech Founded to Save the CEO’s Daughter Goes Public in France

Alma Bio Therapeutics is Aiming to Revolutionize the Treatment of IBD

German Biotech gets Seed Funding to Repurpose Cancer Drugs for the Flu

Cannabinoid Drug Prolongs the Life of Brain Tumor Patients in Phase II Trials

British Synbio’s Llama Antibodies recruited for Cancer T-Cell Therapy

Swiss Parkinson’s Biotech raises Massive €29M in Series B from Top European VCs

French Biotech’s Checkpoint Inhibitor Fails Phase II Leukemia Trial

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!